![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Lynparza Approved for Prostate Cancer
Lynparza Approved for Prostate Cancer
The FDA has approved AstraZeneca’s and Merck’s Lynparza for treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
The approval was based on the results of a phase 3 trial, which showed that Lynparza (olaparib) reduced disease progression or death by 66 percent. It also extended progression-free survival to a median of 7.4 months vs. 3.6 months for patients treated with enzalutamide or abiraterone.
HRR gene mutations occur in approximately 20 percent to 30 percent of patients with mCRPC.
Upcoming Events
-
21Oct